Areas of Focus
- Pharmacology of Cancer and Immune Diseases
- Epigenetics and Metabolism
- Chemical Biology
Work Experience
- 2023-09 to Present - Chinese Academy of Sciences Shanghai Institute of Materia Medica - Researcher
- 2018-09 to 2023-09 - Chinese Academy of Sciences Shanghai Institute of Materia Medica - Associate Researcher
- 2017-08 to 2018-08 - Chinese Academy of Sciences Shanghai Institute of Materia Medica - Assistant Researcher
- 2015-01 to 2017-07 - Chinese Academy of Sciences Shanghai Institute of Materia Medica - Postdoctoral Researcher
- 2006-06 to 2010-08 - Fudan University National Key Laboratory of Genetic Engineering - Research Secretary
- 2005-06 to 2006-06 - Chinese Academy of Sciences Shanghai Institute of Nutrition Sciences - Research Assistant
- 2004-07 to 2005-06 - Fudan University Institute of Genetics - Research Assistant
Academic Background & Achievements
- 2010-09 to 2015-01 PhD in Genetics: Fudan University
- 2000-09 to 2004-06 Bachelor's in Life Sciences: Fudan University
Publications
- Histone deacetylase inhibitor givinostat attenuates nonalcoholic steatohepatitis and liver fibrosis, 11th Author, 2022
- Selective bromodomain and extra-terminal bromodomain inhibitor inactivates macrophages and hepatic stellate cells to inhibit liver inflammation and fibrosis, 11th Author, 2022
- L-5-hydroxytryptophan promotes antitumor immunity by inhibiting PD-L1 inducible expression, 11th Author, 2022
- P300/CBP inhibition sensitizes mantle cell lymphoma to PI3K inhibitor idelalisib, 11th Author, 2022
- PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma, 11th Author, 2021
- Cyclin-dependent kinase inhibitor roscovitine attenuates liver inflammation and fibrosis by influencing initiating steps of liver injury, 11th Author, 2021
- Gossypol, a novel modulator of VCP, induces autophagic degradation of mutant huntingtin by promoting the formation of VCP/p97-LC3-mHTT complex, 2nd Author, 2021
- Covalent Inhibitors Allosterically Block the Activation of Rho Family Proteins and Suppress Cancer Cell Invasion, 3rd Author, 2020
- p300/CBP inhibitor A-485 alleviates acute liver injury by regulating macrophage activation and polarization, 11th Author, 2009
